Treatment
Share your love
FDA issues Complete Response Letter to Sydnexis for SYD-101 pediatric myopia treatment | Ophthalmology Times
The FDA has requested additional evidence for Sydnexis’ SYD-101, a 0.01% atropine eye drop aimed at slowing myopia progression in children, despite positive outcomes from the STAR clinical trial. (Image credit: Ophthalmology Times) The FDA has sent a complete response…
Periorbital rejuvenation: Past, present, and next | Ophthalmology Times
(Image Credit: AdobeStock/Alessandro Grandini) The aesthetic treatment of the periorbital region has evolved significantly, shaped by centuries of innovation and driven by the desire to understand anatomy and how it is affected by aging. Among the earliest documented advancements in…
AAO 2025: Margaret A. Chang, MD, MS, highlights OTX-TKI’s impact on retinal fluid | Ophthalmology Times
Margaret A. Chang, MD, MS, presented updates from the HELIOS Phase 1 trial of OTX-TKI, a sustained-release formulation of the tyrosine kinase inhibitor, axitinib, for the treatment of diabetic retinopathy (DR), at the American Academy of Ophthalmology 2025 annual meeting,…
Throwback Series: Learning when to intervene surgically in glaucoma | Ophthalmology Times
In celebration of Ophthalmology Times’ 50th anniversary, leaders in ophthalmology revisit a memorable “throwback” case from earlier in their careers. In this special series, they reflect on how evolving knowledge, techniques, and technologies have transformed the way such cases are managed…
Systemic chemotherapy reduces mortality in retinoblastoma: 30-year analysis from Iran | Ophthalmology Times
(Image Credit: AdobeStock/Sherry Young) A new study in the International Journal of Retina and Vitreous reported that use of systemic chemotherapy as a mainstay of treatment for retinoblastoma results in significant decreases in mortality and morbidity. Adding targeted chemotherapy reduced…
The mechanics of presbyopia: From muscle movement to functional vision | Ophthalmology Times
(Image Credit: AdobeStock) Presbyopia-correcting eye drops share a common mechanism: They are miotic agents designed to create a smaller pupil. The power of the pupil to extend depth of focus is impressive, as observed in patients with smaller pupils who…
AAO 2025: Early optogenetic therapy shows promise for patients with inherited retinal diseases | Ophthalmology Times
Stephen Tsang, MD, PhD, professor at Columbia University and attending physician at NewYork-Presbyterian Hospital, shared encouraging early findings on the use of optogenetic therapy for patients with retinitis pigmentosa and Stargardt disease. According to Tsang, a single optogenetic treatment has…
Throwback Series: Identifying and treating neovascular lesions in pregnancy | Ophthalmology Times
In celebration of Ophthalmology Times’ 50th anniversary, we invited leaders in ophthalmology to revisit a memorable “throwback” case from earlier in their careers. In this special series, they reflect on how evolving knowledge, techniques, and technologies have transformed the way…
Starting from scratch on neovascular age-related macular degeneration | Ophthalmology Times
(Image Credit: AdobeStock) Luis Arias, MD; and Paolo Lanzetta, MD, recently found themselves on opposite sides of the debate table regarding the value of gene therapy to treat neovascular age-related macular degeneration (nAMD) at the 16th Annual Congress on Controversies…
Q&A: Insights from Rajesh K. Rajpal, MD, on an incision-free keratoconus therapy | Ophthalmology Times
A novel topical, incision-free therapy is now approved to help ophthalmologists slow or halt the progression of keratoconus. (Image credit: AdobeStock/Alessandro Grandini) Glaukos recently received FDA approval for its topical, incision-free therapy for keratoconus (Epioxa) that does not require removal…